. 2018 May 22;124(13):2785–2800. doi: 10.1002/cncr.31551

Table 1.

Age‐Standardized, Delay‐Adjusted Incidence Rates and Fixed‐Interval Trends (2010‐2014) for the Most Common Cancers by Sex, Race, and Ethnicity for Areas in the United States With High‐Quality Incidence Data^a ^, ^b

	All Races^c				White^c				Black^c				API^c				AI/AN (CHSDA)^c				Hispanic^c				Non‐Hispanic^c
Sex/Cancer Site or Type^d	Rank	Rate^e	2010‐2014 AAPC^f	P	Rank	Rate^e	2010‐2014 AAPC^f	P	Rank	Rate^e	2010‐2014 AAPC^f	P	Rank	Rate^e	2010‐2014 AAPC^f	P	Rank	Rate^e	2010‐2014 AAPC^f	P	Rank	Rate^e	2010‐2014 AAPC^f	P	Rank	Rate^e	2010‐2014 AAPC^f	P
All sites^g
Both sexes		453.8	−1.0^h	.001		457.3	−1.0^h	.001		467.5	−1.4^h	<.001		299.1	−0.4^h	<.001		423.4	0.1	.43		356.2	−1.2^h	<.001		465.7	−0.9^h	.002
Males		502.0	−2.2^h	<.001		500.1	−2.1^h	<.001		558.2	−3.0^h	<.001		309.0	−2.6^h	<.001		446.8	−0.5^h	.04		392.6	−2.8^h	<.001		514.7	−2.1^h	<.001
Females		420.6	0.0	.96		428.7	0.0	.59		406.8	0.3^h	<.001		295.8	0.7^h	<.001		409.9	0.6^h	<.001		335.3	0.6	.14		431.5	0.1	.07
Males
Prostate	1	118.2	−7.6^h	<.001	1	110.1	−7.0^h	<.001	1	193.5	−6.0^h	<.001	1	62.5	−9.5^h	<.001	1	86.6	−9.0^h	<.001	1	101.6	−7.8^h	<.001	1	120.2	−7.6^h	<.001
Lung and bronchus	2	73.2	−2.4^h	<.001	2	73.1	−2.3^h	<.001	2	85.8	−3.0^h	<.001	2	46.4	−1.5^h	<.001	2	74.4	−0.5	.16	3	41.4	−2.6^h	<.001	2	76.3	−2.2^h	<.001
Colon and rectum	3	46.5	−1.9^h	.004	3	45.5	−1.9^h	.005	3	56.1	−2.8^h	<.001	3	38.2	−2.2^h	<.001	3	53.2	−1.8^h	.01	2	43.0	−2.7^h	<.001	3	47.0	−1.8^h	.003
Urinary bladder	4	36.8	−0.8^h	<.001	4	39.3	−0.7^h	<.001	5	20.3	0.7^h	<.001	6	15.6	−0.4^h	.03	5	21.5	0.4	.38	7	20.2	−1.9^h	<.001	4	38.3	−0.6^h	<.001
Melanoma of the skin	5	27.4	2.3^h	<.001	5	31.1	2.5^h	<.001	19	1.2	−0.3	.52	18	1.6	0.2	.72	12	10.1	11.7	.12	15	5.1	3.1	.10	5	30.0	2.6^h	<.001
Non‐Hodgkin lymphoma	6	23.7	−0.2	.11	6	24.4	−0.4^h	.02	7	17.6	0.2	.12	5	16.4	0.4	.14	7	18.1	0.1	.94	5	20.6	−0.2	.32	6	24.1	−0.2	.85
Kidney and renal pelvis	7	22.3	1.1^h	.001	7	22.5	0.7^h	.001	4	24.7	1.0^h	.03	9	11.4	2.3^h	<.001	4	31.9	2.1^h	.002	4	21.5	1.0	.21	7	22.5	1.2^h	.001
Leukemia	8	19.0	1.6^h	<.001	8	19.8	1.6^h	<.001	11	14.7	1.0^h	<.001	10	10.4	0.8^h	.03	9	14.0	0.5	.55	8	14.1	0.5^h	.03	8	19.3	1.7^h	<.001
Oral cavity and pharynx	9	17.7	1.3^h	<.001	9	18.3	1.6^h	<.001	10	14.8	−1.9^h	<.001	8	11.7	0.5	.13	8	17.1	1.3	.07	11	10.9	−0.9^h	.003	9	18.6	1.6^h	<.001
Pancreas	10	14.5	1.0^h	<.001	10	14.4	1.1^h	<.001	8	17.0	0.6^h	.003	11	10.3	0.5^h	.04	10	12.6	1.3	.19	10	12.3	0.5^h	.03	10	14.7	1.1^h	<.001
Liver and intrahepatic bile duct	11	12.5	2.8^h	<.001	11	11.3	3.3^h	<.001	6	17.7	2.6^h	.002	4	20.6	−1.7^h	.003	6	20.7	4.6^h	<.001	6	20.4	1.1	.18	11	11.7	2.9^h	<.001
Stomach	12	9.4	−0.3	.13	12	8.6	0.0	.95	12	14.3	−1.8^h	<.001	7	14.3	−2.8^h	<.001	11	11.9	−2.2^h	.01	9	13.1	−2.1^h	<.001	12	9.0	−0.1	.70
Myeloma	13	8.7	2.5^h	<.001	15	8.0	2.3^h	<.001	9	16.9	2.2^h	<.001	13	5.2	2.6^h	<.001	13	8.7	1.8	.11	12	8.5	1.5^h	<.001	13	8.7	2.5^h	<.001
Esophagus	14	8.1	−1.6^h	<.001	14	8.4	−1.3^h	.002	14	7.0	−4.7^h	<.001	15	3.8	−1.0	.10	14	8.1	−0.8	.50	17	4.9	−3.6^h	<.001	14	8.4	−0.9	.21
Brain and other nervous system	15	7.9	−0.2^h	.003	13	8.5	−0.1	.08	15	5.0	0.3	.24	14	4.4	0.3	.32	15	6.1	1.0	.34	13	6.1	−0.5^h	.003	15	8.3	0.0	.95
Thyroid	16	7.3	2.4^h	<.001	16	7.8	2.3^h	.001	16	3.9	4.9^h	<.001	12	7.1	5.6^h	<.001	18	4.8	4.2^h	.01	14	5.5	4.5^h	<.001	16	7.7	2.3^h	<.001
Larynx	17	6.1	−2.3^h	<.001	18	6.0	−2.1^h	<.001	13	8.5	−3.2^h	<.001	16	2.2	−2.9^h	.001	17	5.1	−1.9^h	.04	16	5.0	−3.0^h	<.001	17	6.2	−2.2^h	<.001
Females
Breast	1	125.6	0.4^h	.008	1	126.9	0.4^h	.03	1	125.6	0.7^h	.03	1	94.9	1.7^h	<.001	1	108.8	1.9^h	.001	1	95.3	0.4^h	.03	1	129.5	0.5^h	.002
Lung and bronchus	2	53.3	−1.2^h	<.001	2	55.1	−1.1^h	<.001	2	49.8	−0.9^h	.001	2	28.6	0.2	.07	2	58.1	−2.0^h	.02	3	25.6	−0.8^h	<.001	2	56.2	−1.0^h	<.001
Colon and rectum	3	35.2	−1.7^h	.004	3	34.5	−1.7^h	.02	3	41.5	−2.0^h	.01	3	27.8	−3.5^h	<.001	3	44.1	−0.8^h	.04	2	30.0	−1.1	.11	3	35.9	−1.7^h	.01
Corpus and uterus, NOS	4	26.3	1.2^h	<.001	4	26.8	1.1^h	<.001	4	25.9	2.4^h	<.001	5	18.9	2.2^h	<.001	4	23.5	1.5^h	.005	4	22.7	2.7^h	<.001	4	26.7	1.2^h	<.001
Thyroid	5	21.6	1.9^h	<.001	5	22.7	1.6^h	<.001	6	14.1	2.7^h	.05	4	21.8	1.5	.22	6	16.2	5.9^h	<.001	5	20.5	2.5^h	.002	5	21.9	1.8^h	.001
Melanoma of the skin	6	16.8	1.2^h	.002	6	19.6	1.4^h	<.001	21	1.0	0.4	.38	18	1.3	−0.3	.66	16	6.5	1.7^h	.04	17	4.4	0.2	.51	6	18.7	1.4^h	.001
Non‐Hodgkin lymphoma	7	16.3	−0.4^h	.002	7	16.9	−0.5^h	.001	8	12.5	0.7^h	<.001	6	11.1	0.2	.44	7	14.7	0.2	.80	6	15.7	0.1	.42	7	16.4	−0.4^h	.002
Ovary	8	11.8	−1.6^h	<.001	8	12.2	−1.6^h	<.001	10	9.5	−0.6^h	.002	7	9.6	−0.2	.30	8	11.5	−0.5	.58	8	10.6	−1.3^h	<.001	8	11.9	−1.6^h	<.001
Leukemia	9	11.5	1.4^h	<.001	9	12.0	1.1^h	<.001	11	9.4	2.1^h	<.001	11	6.7	1.1^h	.002	10	9.8	0.6	.53	11	9.7	0.5^h	.02	9	11.6	1.4^h	<.001
Kidney and renal pelvis	10	11.5	0.4^h	.03	10	11.7	0.4^h	.03	7	12.7	−0.1	.89	14	5.1	−0.2	.79	5	18.9	1.7^h	.01	7	12.4	2.0^h	<.001	10	11.4	0.3	.09
Pancreas	11	11.2	1.1^h	<.001	11	10.9	1.1^h	<.001	5	14.6	0.8^h	<.001	8	9.0	0.8^h	.003	9	11.1	0.8	.32	9	10.6	0.6^h	<.001	11	11.3	1.1^h	<.001
Urinary bladder	12	9.1	−0.8^h	<.001	12	9.6	−0.7^h	<.001	14	6.8	−0.3	.19	15	4.0	−0.4	.42	15	6.6	1.8^h	.05	15	5.2	−1.3^h	.001	12	9.5	−0.6^h	<.001
Cervix uteri	13	7.7	−1.0^h	<.001	13	7.5	−0.7^h	.004	12	9.4	−3.7^h	.001	12	6.2	−2.8^h	<.001	11	9.4	−6.3^h	.03	10	9.9	−1.6	.10	13	7.4	−0.8^h	.001
Oral cavity and pharynx	14	6.5	0.8^h	<.001	14	6.7	1.0^h	<.001	15	5.2	−0.8^h	.001	13	5.3	−0.7	.09	14	6.6	0.7	.53	18	4.3	−0.2	.60	14	6.8	0.9^h	<.001
Myeloma	15	5.7	1.6^h	.003	16	5.0	2.3^h	<.001	9	12.5	2.0^h	<.001	16	3.4	1.0	.06	17	5.8	−1.0	.35	14	5.7	2.0^h	.003	16	5.7	1.6^h	.004
Brain and other nervous system	16	5.7	−0.7^h	.008	15	6.1	−0.7^h	.01	17	3.6	0.1	.71	17	3.4	3.7^h	.001	18	3.9	0.1	.95	16	4.6	−1.1^h	<.001	15	5.9	−0.6^h	.03
Stomach	17	4.7	0.1^h	.77	17	4.1	0.5	.32	13	8.0	−1.3^h	<.001	9	8.3	−2.5^h	<.001	13	6.7	−1.5	.09	12	7.9	−1.5^h	<.001	17	4.4	−0.8^h	<.001
Liver and intrahepatic bile duct	18	4.3	3.8^h	<.001	18	4.0	4.5^h	<.001	16	5.2	3.6^h	<.001	10	7.8	−0.5	.05	12	9.2	3.9^h	.002	13	7.8	2.3^h	<.001	18	4.0	4.1^h	<.001

Abbreviations: AAPC, average annual percent change; AI/AN, American Indian/Alaska Native; APC, annual percent change; API, Asian/Pacific Islander; CHSDA, Indian Health Service Contract Health Services Delivery Area; NOS, not otherwise specified.

Source: National Program of Cancer Registries and Surveillance, Epidemiology, and End Results areas reported by the North American Association of Central Cancer Registries as meeting high‐quality incidence data standards for the specified time periods.

The following registries were included in the incidence rates (2010‐2014) and Joinpoint models (1999‐2014) for all races/ethnicities, white, black, AI/AN, API, Hispanic, and non‐Hispanic (42 states): Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Missouri, Montana, Nebraska, New Hampshire, New Jersey, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, Texas, Utah, Vermont, Washington, West Virginia, Wisconsin, and Wyoming.

White, black, API, and AI/AN (CHSDA 2012 counties) include Hispanic and non‐Hispanic; the race and ethnicity categories are not mutually exclusive. AI/AN (CHSDA 2012) statistics exclude data from Kansas.

Cancers are sorted in descending order according to sex‐specific rates for all races/ethnicities. More than 15 cancers may appear under males and females to include the top 15 cancers in every race/ethnicity group.

Rates are per 100,000 persons and were age standardized to the 2000 US standard population (19 age groups; US Bureau of the Census, Current Population Reports, Publication 25‐1130. Washington, DC: US Government Printing Office; 2000 [Census P25‐1130]).

The AAPC is the average APC and is a weighted average of the APCs over the fixed interval from 2010 to 2014 using the underlying Joinpoint model for the period from 1999 to 2014. Joinpoint models with up to 2 joinpoints are based on rates per 100,000 persons and age standardized to the 2000 US standard population (19 age groups; Census P25‐1130). For joinpoint analysis, the Joinpoint Regression Program was used (version 4.5.0.1; Bethesda, MD: Statistical Research and Applications Branch, National Cancer Institute; June 2017).

For all sites, myelodysplastic syndromes are included for the rate calculations but not for the APC calculations; they are excluded from cancer‐specific analysis. Ovary excludes borderline tumors.

The AAPC is statistically significantly different from zero (two‐sided P <.05).